Classification of Lymphomas and Hematological Neoplasia in the Era of Genomic Research: A Themed Issue in Honor of Dr. Elaine S. Jaffe

Dear Colleagues,

This Special Issue is dedicated to a visionary woman in science, Dr. Elaine Jaffe. Her love of biology, dedication to disease discovery and mentorship have shaped hematopathology over the last decades. A singular lymphoma classification, with no differences on either side of the Atlantic, was sculpted by her remarkable work. The microscope served in Dr. Jaffes’s hands as a tool for lymphoma discovery. Through her eyes, multiple neoplasms of lymphoid tissue have been delineated. Through her voice, outstanding hematopathology teaching was spread. This distinguished investigator has advocated for the integration of basic research and clinical diagnosis in the day-to-day work of the hematopathologist. Through this intermingled clinical and investigational research, our understanding of malignant lymphomas’ pathobiology and their relationship with the normal immune system has been enhanced. This has led to unprecedented advancements in prognostication and management of patients with hematological malignancies.

In one of her earliest articles, a Citation Classic (N Engl J. Med l974; 290: 8l3–8l9), Dr Jaffe showed evidence of follicular lymphoma origin from normal follicular B cells. Since then, she has unveiled many pathologically and clinically relevant “guises and disguises” of follicular lymphoma. She described in situ follicular lymphoma, offering clues about the initial genetic changes in follicular lymphomagenesis. She identified histiocytic/dendritic cell tumors occurring with follicular lymphoma, providing the first evidence for the lineage plasticity of mature lymphoid cells. Understanding the genetic and epigenetic events involved in mediastinal B-cell lymphoma biology and, in particular, the mechanisms that cause a B-cell to become a Hodgkin cell and the role of tumor cell interaction with the microenvironment also engaged Dr. Jaffe’s research interest.

The content of this Special Issue promises to be an outstanding “voyage through the eyes of a hematopathologist”, aiming to carry the reader to follow and project the evolution of lymphoma classification, with the discovery of new clinicopathological entities and achieving a better understanding of the molecular mechanisms involved in hematolymphoid neoplasms.

Dr. Alina Nicolae
Prof. Dr. Antonino Carbone
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Hemato is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.